ArticleParasites & vectors2025
Efficacy of an oral combination of afoxolaner and milbemycin oxime for the prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of afoxolaner or a combination of afoxolaner and milbemycin oxime against fleas, ticks, lice and/or intestinal nematodes in dogs naturally infested in two urban areas in Brazil.Parasites & vectors · 2026Article
- Efficacy of lotilaner (CredelioParasites & vectors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanine babesiosis is a tick-borne disease of significant veterinary importance in dogs. It is caused by Babesia canis in Europe, where it is transmitted by Dermacentor reticulatus ticks.
methodsA blinded, randomized, good clinical practice (GCP) and negative control experimental study was conducted to verify the efficacy of NexGard Spectra® in reducing the transmission of B. canis by D. reticulatus to dogs. NexGard Spectra® (IVP) is an oral product for dogs combining afoxolaner, an acaricide/insecticide compound from the isoxazoline class, and milbemycin oxime, a nematicide compound from the macrocyclic lactone class. Three groups of eight dogs were used; one group orally treated on day 0 with the IVP at the minimum recommended dose and two untreated control groups. On day 1, dogs from the treated group and from control group 1 were infested with 50 D. reticulatus adult ticks of 50/50 sex ratio infected with B. canis at a 23% infection rate. On day 28, dogs from the treated group and from control group 2 were infested similarly to those on day 1. Ticks were removed 6 days after each infestation.
resultsSeven to nine days after each infestation, all untreated control dogs displayed clinical signs of canine babesiosis, i.e., lethargy, and/or dark urine, and/or > 39.5 °C rectal temperature. Blood was collected for microscopical blood smear examination, and for polymerase chain reaction (PCR) analysis. The blood smears from all untreated control dogs were positive for Babesia and all the PCR analyses were positive for B. canis. The control dogs were rescue treated. All control dogs were confirmed positive for B. canis by IFA on day 21 (control group 1) and on day 42 (control group 2). None of the IVP-treated dogs expressed any clinical sign of canine babesiosis following each of the two infestations of days 1 and 28 and until day 56. Blood was collected for IFA and PCR analyses from the treated dogs on days 21, 28, 42, and 56, and all results were negative.
conclusionsIn this study, the antiparasitic treatment prevented the transmission of B. canis to dogs following induced infestations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.